UK guidelines for the management of soft tissue sarcomas.

Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. · 2016

Read UK guidelines for the management of soft tissue sarcomas. by Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5109663.txt.

Introduction

Adam Dangoor, Beatrice Seddon, Craig Gerrand, Robert Grimer, Jeremy Whelan, and Ian Judson updated United Kingdom guidelines for soft tissue sarcomas in Clinical Sarcoma Research in 2016. These rare cancers arise in tissues such as muscle and fat almost anywhere in the body, and their many subtypes make firm evidence hard to gather.

The guidelines, first issued in 2010 by the British Sarcoma Group, set out care by specialist teams. Suspected cases should go quickly to a regional sarcoma service, where imaging and biopsy confirm the diagnosis and surgery by a specialist is the usual main treatment. Radiation before or after surgery and drug therapy fit selected cases, and follow-up watches for return or spread. Special sections cover sarcomas of the abdomen's back wall and womb, plus borderline tumors.

Catalog record

CREATORDangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE145 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5109663

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

UK guidelines for the management of soft tissue sarcomas By Adam Dangoor, Beatrice Seddon, Craig Gerrand, Robert Grimer, Jeremy Whelan, Ian Judson Published in: Clinical Sarcoma Research DOI: 10.1186/s13569-016-0060-4 ABSTRACT Abstract Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location means that developing evidence-based guidelines is complicated by the limitations of the data available. However, this makes it more important that STS are managed by teams, expert in such cases, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and the ongoing accumulation of further data and knowledge. The development of appropriate guidance, by an experienced panel referring to the evidence available, is therefore a useful foundation on which to build progress in the field. These guidelines are an update of the previous version published in 2010 (Grimer et al. in Sarcoma 2010:506182, 2010). The original guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices of the British Sarcoma Group (BSG) and were intended to provide a framework for the multidisciplinary care of patients with soft tissue sarcomas. This current version has been updated and amended with reference to other European and US guidance. There are specific recommendations for the management of selected subtypes of disease including retroperitoneal and uterine sarcomas, as well as aggressive fibromatosis (desmoid tumours) and other borderline tumours commonly managed by sarcoma services. An important aim in sarcoma management is early diagnosis and prompt referral. In the UK, any patient with a suspected soft tissue sarcoma should be referred to one of the specialist regional soft tissues sarcoma services, to be managed by a specialist sarcoma multidisciplinary team. Once the diagnosis has been confirmed using appropriate imaging, plus a biopsy, the main modality of management is usually surgical excision performed by a specialist surgeon. In tumours at higher risk of recurrence or metastasis pre- or post-operative radiotherapy should be considered. Systemic anti-cancer therapy (SACT) may be utilized in some cases where the histological subtype is considered more sensitive to systemic treatment. Regular follow-up is recommended to assess local control, development of metastatic disease, and any late-effects of treatment. For local recurrence, and more rarely in selected cases of metastatic disease, surgical resection would be considered. Treatment for metastases may include radiotherapy, or systemic therapy guided by the sarcoma subtype. In some cases, symptom control and palliative care support alone will be appropriate. BACKGROUND Rationale and objective of guidelines Soft tissue sarcomas (STS) are a relatively uncommon group of malignancies. On average a general practitioner may only see one sarcoma in their career. To improve diagnosis and treatment of these tumours, management was rationalized to peer-reviewed regional soft-tissue sarcoma services, and a smaller number of specialist units which also treat primary bone tumours [1]. An outline of best practice was set out in the National Institute for Health and Clinical Excellence Improving Outcomes Guidance for people with sarcoma (NICE-IOG) [2] published in 2006. These guidelines are an attempt to review current evidence concerning soft-tissue sarcoma diagnosis and treatment, and provide recommendations to support best practice. They are not intended to be prescriptive, but aim to improve the quality of care for patients with STS by helping identify and inform the key decisions involved in their management. They will hopefully provide a useful resource for sarcoma services to help guide multidisciplinary team (MDT) case discussions, and patient management. Methods This updated guideline has been authored and reviewed by specialists from the UK involved in diagnosing and treating patients with sarcoma. They include members of the British Sarcoma Group (BSG), and NHS England Sarcoma Clinical Reference Group (CRG). As with the previous version, current NICE, NCCN (National Comprehensive Cancer Network, US), and ESMO (European Society for Medical Oncology) guidance were referenced, tailoring the recommendations for UK practice. It provides a brief review of the current state of established knowledge in sarcoma diagnosis and management, with guidance on what is considered current best practice in the UK. It has been derived by a consensus of expert opinion based on their interpretation of currently available data, and their own clinical experience. Scope of guidelines These recommendations apply principally to soft tissue sarcomas arising from limbs and trunk and although, where appropriate, specific guidance is given according to histological subtype it is recognised that some tumours, for example, Ewing sarcoma, and embryonal and alveolar rhabdomyosarcoma, require a different approach to management, and are excluded from this guidance [3]. These rare subtypes are relatively more common in paediatric and young adult patients. Ewing sarcoma arising in soft tissue are managed in accordance with guidelines for Ewing sarcoma of bone (see UK bone sarcoma guidelines [4]). Rhabdomyosarcoma is the commonest sarcoma in children and appropriately managed by children’s cancer multidisciplinary teams (MDTs), often within international clinical trials such as EpSSG RMS 2005 [5, 6] which include comprehensive treatment guidance. For other histologies arising in children and young people (often referred to as non-rhabdomyosarcoma, soft tissue sarcomas, NRSTS) much less evidence exists for optimal management, in particular the application of chemotherapy and radiotherapy. Close working between children’s cancer MDTs and sarcoma MDTs should be regarded as best practice. Specific recommendations on the management of retroperitoneal and uterine sarcomas, as well as aggressive fibromatosis (desmoid tumours), plus some other conditions referred commonly to sarcoma MDTs, are included separately within this guideline. Bone sarcomas and gastrointestinal stromal tumours (GISTs) are subject to their own specific BSG guidelines. The latest bone sarcoma guidelines have recently been published [4] and the GIST guidelines are currently being updated. These guidelines focus on clinical effectiveness, giving a picture of what treatments a specialist sarcoma multidisciplinary team should have access to within the UK, subject to some flexibility to allow for evolving practice, but they do not employ the same detailed analysis of cost effectiveness as NICE. In rare situations, treatment options may be suggested where NHS funding is not established. Unfortunately, with rare tumours such as sarcoma, NICE, and the Cancer Drugs Fund (CDF), may be less likely to evaluate potential treatments. These guidelines can be considered to represent a broad consensus in 2016. They will require updating as knowledge and treatment evolve. Specialised soft-tissue sarcoma services Following the publication of the National Institute for Health and Clinical Excellence Improving Outcomes Guidance for people with sarcoma (NICE-IOG) [2] in 2006, the services for patients with sarcoma in England and Wales were centralised. There are currently five centres providing both bone and soft-tissue sarcoma services, and an additional ten centres who diagnose and treat only soft-tissue sarcoma, passing on referrals of suspected bone sarcomas to their regional bone sarcoma centre [7] and collaborating on aspects of management. In England, services are commissioned and delivered in accordance with the current NHS England service specification [8]. In Scotland, the Scottish Sarcoma Network coordinates care of patients at five centres, and in Northern Ireland all bone sarcomas are managed at Musgrave Park Hospital with soft-tissue sarcomas also seen at four other centres. Each specialist service must have a multidisciplinary team (MDT) made up of radiologists, surgeons, medical and clinical oncologists, pathologists, specialist nurses, and an

Read the complete text